Introduction
The widespread utilization of single-antigen bead (SAB) assays prior to kidney transplantation has improved the detection of donor-specific antibody (DSA) in potential transplant recipients. Many studies have documented inferior renal graft outcomes in the presence of pretransplant DSA (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . However, the clinical importance of such DSA in the setting of a negative flow cytometry crossmatch (FCXM) at transplant remains controversial and the need for desensitization uncertain. There are limited published data regarding the impact of specific DSA characteristics such as class, strength or whether DSA persisted posttransplant on renal allograft outcomes when flow cytometry is negative. Additionally, the clinical significance of waxing/waning HLA antibodies pretransplant that are donor specific has not been reported in detail.
The use of desensitizing agents prior to transplant for those patients at increased immunologic risk based on pretransplant screening has permitted successful transplantation for those who may not otherwise have had access to this treatment, despite higher acute rejection rates and inferior graft survival compared to those without preformed DSA (16, 17) . Clinical experience has shown these treatments to be necessary for patients with high-risk immunologic screening assays (complement-dependent cytotoxicity crossmatch [CDC] and/or FCXM positivity); however, the necessity of these costly therapies in the setting of SAB positivity alone remains uncertain, with practices varying center by center (17, 18) .
Since September 2007, all renal transplant recipients at our center have undergone immunologic screening with both SAB and FCXM assays prior to transplantation. The aim of this study was to evaluate the impact of pretransplant DSA in the setting of negative FCXM screening on intermediate-term renal allograft outcomes in patients not receiving desensitization therapy. To our knowledge, this is the largest study of outcomes following kidney transplantation in the setting of low-level pretransplant DSA with negative FCXM to date.
Materials and Methods

Patient population
This retrospective analysis included adult patients (≥18 years old) receiving a kidney or kidney-pancreas transplant at the University of Colorado Hospital between September 2007 and August 2012. Patients with positive FCXM and those who received desensitization therapy were excluded from analysis. The study was approved by the Colorado Multiple Institution Review Board.
All HLA testing, antibody analyses and crossmatches were performed by American Board of Histocompatibility and Immunogenetics (ABHI) boardcertified technologists and reviewed by ABHI board-certified HLA specialists in an ASHI-and College of American Pathologists (CAP)-accredited laboratory (ClinImmune Labs, Aurora, CO) with 100% majority consensus on proficiency training for both antibody detection and flow crossmatching during the study period.
HLA typing and panel-reactive antibody (PRA) analysis
Recipients were typed by serology at HLA-A, -B, and -Cw and HLA-DR/ DQ by sequence-specific oligonucleotide (SSO, LabType, One Lambda, Canoga Park, CA) with sequence specific primer (SSP) and sequencing used as necessary. Donors were typed by the organ recovery center and resolved in a similar manner by SSO, SSP, and sequencing as needed. The calculated PRA (cPRA) was determined using the Organ Procurement and Transplantation Network calculator (https://optn.transplant.hrsa.gov/resources/allocation-calculators/cpra-calculator/) for any HLA-A, -B, -DR and -DQ antigens with an MFI greater than 2000 in the One Lambda single-antigen assay.
Pretransplant crossmatch
Cell-based FCXM was performed on current and historic (up to 6 months preceding transplant) recipient sera to detect antibodies against donor T or B cells. Briefly, mononuclear cells were isolated from whole blood (with RosetteSep, STEMCELL Technologies Inc., Vancouver, BC, Canada) or lymph nodes and treated with 0.5 mg/mL pronase for 30 min at 37°C, followed by a brief deoxyribonuclease treatment. The cells were then washed and incubated with patient sera (200 000 cells/20 lL serum and 30 lL RPMI) for 30 min at room temperature, followed by three washes and addition of an antibody cocktail containing CD3 PerCP-Cy5.5, CD19 PE, BD Biosciences and APC-AffiniPure F(ab) 0 2 goat antimouse IgG (Jackson ImmunoResearch, West Grove, PA) for 20 min and two more washes. Cell data events were acquired and analyzed with the FACSArray Bioanalyzer (Becton Dickinson, Franklin Lakes, NJ). A positive FCXM was validated at more than 2 standard deviations above the mean of negative control sera and defined as ≥330 MFI units for T cells and ≥1000 MFI for B cells. Positive FCXM sera were tested for DSA using LABScreen SAB (One Lambda). The dynamic range for both the T and B flow crossmatches was 50-20 000 MFI.
Pre-and posttransplant DSA screening
Kidney and kidney-pancreas transplant recipients on the waiting list were screened for pretransplant HLA antibodies monthly. Following transplant, DSA screening was performed at 1, 6 and 12 months and annually. Patients were also screened whenever clinically indicated (graft dysfunction). Patients were screened for both class I and class II antibodies using LABScreen Mixed beads (One Lambda). Positive tests were quantified using SAB (One Lambda) per the manufacturer's specifications. DSA were defined as an MFI greater than twofold above the negative control and an absolute MFI of greater than 500. All MFIs were normalized against negative control beads per the manufacturer's instructions. Positive beads were analyzed for mismatched donor antigens (or alleles) at HLA-A, -B and -DR loci to identify DSA. MFI values for each sample were recorded for each DSA. Additional donor and recipient molecular typing was performed to confirm donor specificity to HLA-C, DPB1, DQB1, and DQA1 when indicated.
Immunosuppression
In general, induction therapy with rabbit antithymocyte globulin (rATG, thymoglobulin) was utilized for living, nonrelated kidney and kidney-pancreas transplant recipients and those considered to be at higher immunologic risk (pretransplant cPRA greater than 20%, repeat transplant, African American race, cold ischemia time greater than 24 h). Otherwise, low-risk deceased donor and living-related donor recipients received no induction. IL2-RA (basiliximab) was used as induction therapy when part of clinical trial protocols. Most patients were placed on triple immunosuppression therapy, including tacrolimus, mycophenolate and steroids, with a minority receiving mammalian target of rapamycin inhibitor in place of mycophenolate. A smaller minority received experimental immunosuppressive regimens (sotrastaurin, tofacitinib, alefacept, and belatacept), as dictated by various clinical trial protocols (Table 1) .
Clinical outcomes
Acute rejection (AR) was diagnosed clinically and pathologically in accordance with Banff '07 criteria (19) . Clinical rejection was defined by acute kidney injury in the absence of other causes and a response to high-dose corticosteroid (500 mg daily for 3-5 days) and/or rATG 1.5 mg/kg/day for 5-7 days with reduction in serum creatinine to baseline. If screening for DSA was negative at the time of treatment, this was defined as clinically diagnosed T cell-mediated rejection. Mixed acute humoral/cellular rejection was treated with plasmapheresis/intravenous immunoglobulin, with or without concurrent thymoglobulin as indicated. C4d was detected using immunohistochemistry. Graft function was assessed by the estimated glomerular filtration rate (eGFR) calculated by the four-variable modification of renal disease (MDRD) equation (20) . Graft failure was defined as a return to hemodialysis dependence or retransplant. Spot urine protein/creatinine ratios (mg/g) were used to estimate daily protein excretion. Proteinuria data were recorded at 1, 3, 6, and 12 months and then yearly. Four patients with recurrent primary focal segmental glomerulosclerosis (FSGS) were excluded from the proteinuria data analysis.
Properties of pretransplant DSA identified for analysis DSA identified at any time pretransplant were included in the analysis. DSA groups based on class were described as class I, class II or mixed. Patients with pretransplant DSA (DSA(+)) were divided into three groups depending on the period the antibodies were last detected in relationship to transplant dates: (1) those with pretransplant DSA present more than 6 months prior to transplant and absent thereafter, (2) within 6 months of transplant but absent at final crossmatch and (3) those with DSA detected at final crossmatch. When assigning a time of detection category, the most recent DSA detected were used. For the DSA strength analysis, patients with pretransplant DSA were divided into three groups based on MFI strength: <1000, 1000-2999, and ≥3000. When assigning a strength category to patients with multiple DSA, the maximum MFI was used. Persistence of pretransplant DSA was defined as the presence of DSA at any time after renal transplant. Table 1 were compared by DSA status using exact chi-squared and two-sample t-tests. Kaplan-Meier probabilities of graft and patient survival were plotted and compared by DSA status using log-rank tests. Cox's regression model was used to obtain estimates of hazard ratios for univariate analyses and also to compare DSA status allowing for age, gender, ethnicity, donor type, cPRA, number of HLA mismatches, induction therapy, and retransplant status. Development of posttransplant DSA was analyzed as a time-dependent covariate. Probability of AR was compared between DSA groups using logistic regression. Estimates of relative risk, adjusting for age, gender, ethnicity, donor type, cPRA, number of HLA mismatches, induction therapy and retransplant status, were calculated using Poisson regression with a robust variance estimator (21) . A mixed-effects model with follow-up visit (1, 2, 3 or 4 years) as a class variable was used to analyze differences between groups for eGFR and proteinuria over time. The number of patients with eGFR and proteinuria at 5 years was too small for reliable estimates, so these outcomes were modeled between 1 and 4 years only. DSA groups were compared overall using a test of simple effects (22) in which the effect of DSA group was tested for each year posttransplant. Proteinuria was analyzed using a log transformation, as it was not normally distributed, and confidence intervals estimated from the models were back transformed to a linear scale. Last recorded eGFR and log proteinuria values were compared between groups using a general linear model for all available data to 5 years posttransplant. Study data were collected and managed using REDCap electronic data capture tools American Journal of Transplantation 2016; XX: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] hosted at the University of Colorado Denver. Initial data were extracted from the United Network for Organ Sharing database for our center; then, local data were supplemented to provide greater detail. All analysis was performed using SAS version 9.4 (SAS Inc., Cary, NC).
Statistical methods
Patient characteristics in
Results
Demographics and baseline characteristics There were 690 kidney and kidney-pancreas recipients between September 1, 2007, and August 31, 2012. Seventeen patients who were FCXM positive, eight patients with a history of desensitization treatment and five patients with primary nonfunction were not included in the analysis, reducing the data set to 660 transplants. Two patients had two transplants in this period, resulting in 660 transplants in 658 patients with a median follow-up of 4.2 years. One hundred and sixty-two (24.5%) patients had pretransplant DSA detected at any time pretransplant, 68 of whom had more than one DSA. Baseline characteristics for all patients, DSA-positive (DSA(+)) and DSA-negative (DSA(À)) cohorts are shown in Table 1 . DSA(+) patients were more likely to be female, African American or Hispanic; have a repeat transplant; receive a deceased donor allograft; have more HLA mismatches; have higher cPRA at transplant; and receive rATG induction at the time of transplant. The number of patients in each DSA(+) subgroup is shown in Table 2 . Details for DSA(+) patients with 0% cPRA are available in Table S1 .
AR One-year acute rejection (AR) rates were similar between DSA(+) and DSA(À) patients (15.4% vs. 11.4%, respectively; p = 0.18; Figure 1 ). There was an increase in the AR rate with increasing pretransplant DSA strength and notably for those with MFI greater than 3000 (26.3% vs. 11.4%) in DSA(À) patients; however, this failed to reach statistical significance in univariate analysis (p = 0.24 for the group and p = 0.06 comparing >3000 MFI to DSA(À); Figure 1B ).
There was no statistically significant association between 1-year AR rates and pretransplant HLA class ( Figure 1C ), although rates were higher in those with class II DSA. Rejection in patients with class II DSA was not attributable to a specific locus (DQ vs. DR vs. DP; data not shown).
The timing of pretransplant DSA detection (>6 months and ≤6 months pretransplant vs. detection at final crossmatch) was not associated with significant differences in 1-year AR when compared to those without pretransplant DSA (p = 0.51; Figure 1D ). Table S2 shows patient numbers with and without AR in each DSA subclass.
Posttransplant persistence (or recurrence, in circumstances of historical DSA) of DSA was identified in 112 patients. Posttransplant persistence and/or recurrence of pretransplant DSA was associated with significantly higher AR (p = 0.008; Figure 1E ). However, the timing of posttransplant detection of recurrent pretransplant DSA (relative to the onset of AR) was not associated with AR incidence. The median time to detection of posttransplant DSA (by either protocol or indication screening) was 32 days (IQR of 27-181 days). AR within the first year posttransplant occurred in 23 patients with persistent/recurrent DSA(+). Of these 23, 10 patients had persistent/recurrent posttransplant DSA detected prior to the rejection episode, 10 had persistent/recurrent posttransplant DSA detected after the rejection episode and 3 had persistent/recurrent posttransplant DSA detected concurrent with rejection.
In multivariable analysis, the presence of pretransplant DSA (not otherwise characterized) was not associated with an increased risk of 1-year AR. However, pretransplant DSA MFI strength of greater than or equal to 3000 was associated with increased risk of 1-year AR Figure 2 shows the 5-year Kaplan-Meier death-censored graft survival in patients with and without pretransplant DSA and in those with DSA as categorized by strength, class, timing, and persistence posttransplant. Five-year death-censored graft survival was similar when comparing DSA(+) patients (89.0%) vs. DSA(À) patients (90.6%, p = 0.53; Figure 2A ) and when comparing various DSA strengths: <1000 (88.7%), 1000-3000 (89.2%), ≥3000 (89.2%), and no DSA (90.6%) (p = 0.92; Figure 2B ).
Graft survival
The class of pretransplant DSA also did not correlate with 5-year death-censored graft survival when compared to the DSA(À) group (91.9% in class I vs. 84.2% in class II vs. 85.3% in mixed class I + II vs. 90.6% in the DSA (À) group, respectively; p = 0.65; Figure 2C ), nor did the timing of pretransplant DSA detection (79.3% vs. 92.0% vs. 90.0% vs. 90.6% for DSA detected more than 6 months and less than or equal to 6 months pretransplant, detection at final crossmatch and no DSA, respectively; p = 0.57; Figure 2D ). Those with persistence/ recurrence of pretransplant DSA experienced a nonsignificant decrease in 5-year death-censored graft survival when compared to those with pretransplant DSA only versus DSA(À) (85.5% vs. 96.8% vs. 90.6%, respectively; p = 0.06; Figure 2E ).
In multivariable analysis, the presence of pretransplant DSA (not otherwise characterized) was not associated with an increased risk of 5-year graft loss (hazard ratio = 0.97, p = 0.93; Table 4 ). Similar multivariable analysis for DSA strength, HLA class, timing of detection or persistence/recurrence did not show a significantly increased risk of 5-year graft loss for the DSA(+) group versus the DSA(À) group (Table 4) .
Glomerular filtration rate (GFR) and proteinuria
Graft function was estimated by the MDRD GFR at 1, 2, 3, and 4 years posttransplant. Comparisons between time points with mixed-effects models showed lower eGFR in the DSA(+) cohort (overall) compared with the DSA(À) group at year 3 (54.0 mL/min vs. 58.3 mL/min, p = 0.050) and nonsignificant reduction at year 4 (52.5 mL/min vs. 57.1 mL/min, p = 0.12; Figure 3A ). Similar analyses for DSA characteristics, including HLA class, timing of detection and persistence/recurrence of pretransplant DSA, did not show a significant risk of lower eGFR for overall comparisons between the DSA(+) and DSA(À) cohorts. There was a significant difference in eGFR between subgroups comparing maximum MFI strength at 3 years posttransplant (p = 0.028; Figure 3B ) but not at 4 years posttransplant. However, only 9 of the initial 19 patients in this subgroup had data at this time point. Proteinuria analyses were performed at 1, 2, 3, and 4 years posttransplant using mixed-effects models to compare between time points. Four patients with a history of recurrent FSGS were excluded from the analysis. There was no significant difference in proteinuria over time between the DSA(+) cohort (not otherwise characterized) and the DSA(À) cohort ( Figure 4A ). There was a significant difference in proteinuria when comparing the subgroups with a maximum DSA strength of less than 3000 versus greater than or equal to 3000 versus DSA(À) (p = 0.045) at year 3 posttransplant; however, only 5 of the initial 19 patients with a maximum MFI strength greater than or equal to 3000 had data available at this time point. Similar analysis for DSA characteristics, including HLA class, timing of detection or persistence/recurrence of pretransplant DSA, did not show a significant risk of proteinuria (Table S3 shows the last available eGFR and proteinuria 1-5 years posttransplant).
Using a cutoff of 1000 DSA for defining the presence of pretransplant DSA and categorizing as 1000 to <2000, 2000 to <3000 and ≥3000 MFI did not show any differences in results or interpretation from the analysis using a cutoff of 500 MFI (data not shown).
Discussion
In this article, we describe the characteristics and clinical impact of pretransplant DSA in 660 consecutively transplanted kidney or kidney-pancreas recipients with a negative pretransplant FCXM in the absence of desensitization therapy. We found an incidence of E) were only statistically significant for strength of DSA at 3 years posttransplant, but patients with MFI greater than or equal to 3000 did not have significantly lower eGFR than those without DSA. *Based on nine patients at 3 years with MFI greater than or equal to 3000 and eGFR data. CI, confidence interval; DSA, donor-specific antibodies; eGFR, estimated glomerular filtration rate; MFI, mean fluorescence intensity; Post-Tx, posttransplant; PreTx, pretransplant; Xmatch, crossmatch.
pretransplant DSA at any point prior to transplant in 25% of recipients. Taken in aggregate, pretransplant DSA with a negative FCXM did not significantly impact AR rates, graft function (GFR or proteinuria) or intermediate-term graft survival. While pretransplant DSA with MFI greater than or equal to 3000 (detected at any time prior to transplant) was associated with a significantly higher AR risk in multivariable analysis, this did not translate into inferior graft survival. To our knowledge, this study is the first to evaluate the clinical significance of historically identified FCXM-negative DSA and is the largest and most comprehensive study to date evaluating DSA in the setting of a negative FCXM. These data have important implications for pretransplant risk stratification and the utilization of desensitization therapies.
Several small studies have reported clinical outcomes in patients with pretransplant DSA in the setting of a negative FCXM with variable conclusions (1-7). The results of these studies were pooled in a recent meta-analysis (23), which included a total of 145 patients with pretransplant DSA and reported an increased incidence of AMR (25% vs. 11%) and a significant decrease in graft survival in the presence of pretransplant DSA versus those without. These data are limited, however, by small individual sample sizes, variable follow-up periods (ranging from 8 to 60 months) and inconsistent use of desensitization therapies. In addition to these limitations, this analysis was weighted heavily by the study by Willicombe et al (5) due to a sample size of 480 patients (44 with DSA). This study did not include B cell FCXM in the pretransplant screening process, and a majority of class II DSA was of strength likely to result in positive FCXM.
By comparison, our study analyzed a significantly larger cohort (n = 660, 162 with DSA), and all patients included in the current study underwent consistent T cell and B cell FCXM screening prior to transplant, with none receiving desensitization therapy. This enables more accurate associations between nondesensitized FCXMnegative pretransplant DSA and graft outcomes, as well as additional analyses of pretransplant DSA subgroups that may be considered at higher or lower risk for poor outcomes.
Our ability to draw firm conclusions on the association between pretransplant DSA and longer-term graft outcomes is limited by the intermediate follow-up period (median of 4.2 years) of this study. However, proteinuria is associated with an increased risk of graft failure in patients with DSA and may be considered an early marker for eventual graft loss (7, 24) . We report similar degrees of proteinuria in patients with and without pretransplant DSA throughout the duration of our study. Interestingly, we also found a lower GFR in the DSA(+) group starting from 3 years posttransplant; however, this was of borderline significance at 3 years and did not reach statistical significance at 4 years. While this did not translate to inferior graft survival at 5 years, this finding warrants further study and follow-up, as GFR may also be considered a surrogate for future graft survival.
Attempts have been made in various studies to identify specific characteristics of pretransplant DSA associated with inferior graft outcomes. However, only a handful of studies have reported these findings in the setting (2) did not report increased risk of AMR or worse graft survival in their study population with recurrent pretransplant DSA (n = 4). Likewise, our study did not demonstrate an increased risk of 1-year AR nor worse 5-year graft survival after multivariable analysis in a considerably larger cohort (n = 112). The timing of the posttransplant persistence/recurrence of the DSA detection relative to AR onset was also not predictive of AR.
To our knowledge, there are no studies on the impact of pretransplant DSA strength or the effect of waxing/ waning DSA (the timing of detection) in the setting of negative FCXM. Our study shows an increased 1-year risk of AR in patients with pretransplant DSA MFI greater than or equal to 3000 without an impact on 5-year deathcensored graft survival. We did not find a significant association between DSA detection time relative to transplant and graft outcomes. In contrast, Lefaucheur et al (13) showed an increased risk of AMR when DSA is present both historically and at the time of final crossmatch compared to historical DSA only (40% vs. 27%); however, the patients in this study did not undergo FCXM testing.
Our study identified pretransplant DSA in 25% of FCXMnegative patients included in our cohort. This incidence has been variable (5-33%) in reports (1-7) and is due to multiple factors, including the use of different MFI cutoffs for HLA antibody positivity, the sensitivity and specificity of different antibody detection methods and the DSA HLA loci included in the analysis. Our incidence of 25% is higher than a number of reports of pretransplant DSA formation, likely due to our threshold of 500 MFI for positive results, and our comprehensive evaluation of mismatches at HLA-DP, -DQ, and -Cw loci. We believe that an MFI cutoff of 500 is justified, as MFIs as low as 100 have been reported as pathogenic (25) . Increasing the cutoff to 1000 in a sensitivity analysis did not change our findings.
Strengths of this study include the number of patients with pretransplant DSA (162) not undergoing desensitization therapy and the consistent use of pretransplant FCXM screening. Our ability to analyze pre-and posttransplant production of DSA in patients receiving similar immunosuppression regimens consistent with modern treatment protocols and robust HLA antibody analyses with molecular typing for allele-level antibodies against HLA-A, -B, -C, -DRB1, -DPB1, DQB1-and DQA1 antigens supports the conclusions reached in this study. The main limitations to this study are the retrospective design, leading to potential inconsistencies in the capturing of clinical events, and a median follow-up of 4.2 years, which limits our ability to draw firm conclusions on longer-term graft survival. Protocol biopsies were not performed during the study inclusion dates, and we are unable to report subclinical pathology in this cohort. Despite the use of high-resolution typing to confirm donor specificity, the presence of denatured HLA antigens and the combinations of class II alpha and beta chains introduce the possibility of occasional false positivity.
In summary, the data presented in this report suggest that pretransplant DSA carries minimal clinical risk when associated with negative FCXM in a cohort of patients not receiving desensitization therapy. While acknowledging that further follow-up is required in order to draw firm conclusions regarding the risk of longer-term graft attrition, we do not recommend withholding transplant for patients falling into this category of pretransplant immunologic testing and suggest reserving desensitization therapy for those patients exhibiting higher degrees of donor-specific immunologic risk.
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